Today’s Stock Market in 2-Minutes
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
Patrick Gruber, CEO of Gevo (NASDAQ: GEVO), shares how the company is pioneering renewable, drop-in hydrocarbon jet fuels that are cost-competitive with traditional petroleum-based alternatives. With over 450 patents and projects backed by a $1.63B DOE loan guarantee, Gevo is scaling commercial production through facilities in South Dakota and North Dakota. The company’s ethanol-based jet fuel, carbon capture, and RNG assets are unlocking significant revenue streams—positioning Gevo to become EBITDA positive in 2025. With $270M+ in cash, strategic partnerships, and bipartisan support for 45Z tax credits, Gevo is accelerating the transition to net-zero aviation fuels.
May 22, 2025FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer certification for a luer lock vial already used in three FDA-approved ANDA products with 11.9 million units shipped over the past 12 months without complaints, returns, adverse events, or recalls. […]
August 7, 2026
NEW YORK and TOKYO, Aug. 07, 2026 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, has entered into an agreement to transfer its entire 51% equity interest in HeartCore Luvina Vietnam Company Limited (“HCLV”), the Company’s Vietnam-based software development joint venture, to Luvina Software Joint […]
August 7, 2026
Geneva, Switzerland , Aug. 07, 2026 (GLOBE NEWSWIRE) — August 7, 2026 — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a global leader in secure semiconductors, PKI and post-quantum cybersecurity technologies, outlines today how its SEALQuantum.com Sovereign Quantum Vertical Stack (“Stack”) is interconnecting the growing roster of partners and portfolio companies within the SEALQUANTUM.com […]
August 7, 2026
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended June 30, 2026. “While we were disappointed with the outcome of the Phase […]
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026
August 7, 2026